{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"13"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"8"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"13"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment.","groups":[{"description":"Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG000","title":"Participants With NMC"},{"description":"Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Participants With SCLC"},{"description":"Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG002","title":"Participants With CRPC"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG003","title":"Participants With TNBC"},{"description":"Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG004","title":"Participants With ER+BC"},{"description":"Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762","id":"OG005","title":"Participants With GIST"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Number of Participants With AEs and SAEs-Part 2","type":"PRIMARY","unitOfMeasure":"Participants"}